Country: Canada
Language: English
Source: Health Canada
BIMATOPROST
ABBVIE CORPORATION
S01EE03
BIMATOPROST
0.01%
SOLUTION
BIMATOPROST 0.01%
OPHTHALMIC
15G/50G
Prescription
PROSTAGLANDIN ANALOGS
Active ingredient group (AIG) number: 0147303002; AHFS:
APPROVED
2009-09-01
_Page 1 of 30_ _Lumigan RC (bimatoprost)_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LUMIGAN RC® bimatoprost ophthalmic solution Solution, 0.01% w/v, for ophthalmic use Elevated Intraocular Pressure Therapy Prostamide Analogue (ATC Code: S01EE03) AbbVie Corporation 8401 Trans-Canada Highway St-Laurent, Quebec H4S 1Z1 Submission Control Number: 266431 Date of Initial Authorization: SEP 24, 2009 Date of Revision: SEP 9, 2022 _ _ _Lumigan RC (bimatoprost) _ _Page 2 of 30 _ TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics .................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ........................................................ 4 4.4 Administration ......................................................................................................... 4 4.5 Missed Dose ............................................................................................................. 4 5 OVERDOSAGE ............................................................................................................ 5 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................ 5 7 WARNINGS A Read the complete document